| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 25 | 2022 | 132 | 5.470 |
Why?
|
| CD8-Positive T-Lymphocytes | 20 | 2022 | 266 | 3.930 |
Why?
|
| Neoplasms | 26 | 2022 | 1667 | 3.810 |
Why?
|
| Immunotherapy | 27 | 2022 | 215 | 3.410 |
Why?
|
| T-Lymphocytes | 23 | 2022 | 597 | 3.330 |
Why?
|
| Melanoma | 16 | 2022 | 335 | 3.170 |
Why?
|
| Th17 Cells | 11 | 2021 | 116 | 3.080 |
Why?
|
| T-Lymphocyte Subsets | 12 | 2021 | 126 | 2.390 |
Why?
|
| Lymphocyte Activation | 19 | 2021 | 397 | 2.120 |
Why?
|
| Adoptive Transfer | 12 | 2018 | 100 | 1.680 |
Why?
|
| Melanoma, Experimental | 8 | 2019 | 95 | 1.500 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2019 | 135 | 1.490 |
Why?
|
| Immunologic Memory | 6 | 2018 | 75 | 1.200 |
Why?
|
| Cytokines | 9 | 2022 | 866 | 1.160 |
Why?
|
| Tumor Microenvironment | 6 | 2022 | 213 | 1.110 |
Why?
|
| Animals | 57 | 2023 | 20881 | 1.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2021 | 91 | 1.070 |
Why?
|
| Interleukin-17 | 6 | 2018 | 62 | 1.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2020 | 226 | 1.020 |
Why?
|
| Mice | 37 | 2023 | 8474 | 1.010 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2021 | 199 | 0.970 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 3 | 2021 | 8 | 0.920 |
Why?
|
| Folic Acid | 6 | 2016 | 123 | 0.920 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 2 | 2021 | 8 | 0.920 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 18 | 0.920 |
Why?
|
| Interleukin-12 | 4 | 2016 | 75 | 0.830 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 4 | 2016 | 9 | 0.830 |
Why?
|
| Dipeptidyl Peptidase 4 | 2 | 2020 | 15 | 0.790 |
Why?
|
| Mice, Inbred C57BL | 19 | 2022 | 2791 | 0.760 |
Why?
|
| B-Lymphocytes | 2 | 2022 | 329 | 0.730 |
Why?
|
| Interleukin-2 | 7 | 2018 | 133 | 0.720 |
Why?
|
| Autoimmunity | 3 | 2018 | 118 | 0.720 |
Why?
|
| Humans | 60 | 2022 | 68618 | 0.690 |
Why?
|
| Energy Metabolism | 1 | 2021 | 222 | 0.660 |
Why?
|
| Mesothelioma | 2 | 2017 | 21 | 0.660 |
Why?
|
| Programmed Cell Death 1 Receptor | 6 | 2022 | 87 | 0.650 |
Why?
|
| Signal Transduction | 12 | 2021 | 2689 | 0.650 |
Why?
|
| Whole-Body Irradiation | 5 | 2015 | 52 | 0.640 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 376 | 0.620 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2021 | 66 | 0.610 |
Why?
|
| Biomarkers, Tumor | 5 | 2022 | 508 | 0.610 |
Why?
|
| Cellular Senescence | 1 | 2017 | 112 | 0.540 |
Why?
|
| Skin Neoplasms | 4 | 2022 | 375 | 0.530 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 446 | 0.520 |
Why?
|
| Receptors, Cell Surface | 4 | 2016 | 248 | 0.510 |
Why?
|
| Macrophages | 6 | 2021 | 647 | 0.510 |
Why?
|
| Mouth Neoplasms | 3 | 2021 | 206 | 0.480 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 37 | 0.480 |
Why?
|
| Microbiota | 1 | 2015 | 80 | 0.470 |
Why?
|
| Cell Line, Tumor | 13 | 2018 | 1851 | 0.460 |
Why?
|
| Arthritis, Experimental | 3 | 2016 | 38 | 0.450 |
Why?
|
| Lymphocyte Depletion | 7 | 2018 | 34 | 0.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 756 | 0.440 |
Why?
|
| Cell Differentiation | 4 | 2015 | 1034 | 0.430 |
Why?
|
| Carrier Proteins | 3 | 2004 | 597 | 0.420 |
Why?
|
| Toll-Like Receptors | 2 | 2015 | 56 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 511 | 0.400 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2021 | 629 | 0.390 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 27 | 0.370 |
Why?
|
| Neoplasms, Experimental | 2 | 2009 | 118 | 0.360 |
Why?
|
| Immunomodulation | 4 | 2019 | 35 | 0.360 |
Why?
|
| Antigen-Presenting Cells | 2 | 2021 | 50 | 0.350 |
Why?
|
| Receptors, Immunologic | 1 | 2009 | 72 | 0.340 |
Why?
|
| Interleukin-15 | 4 | 2018 | 66 | 0.340 |
Why?
|
| Cell Proliferation | 8 | 2021 | 1174 | 0.340 |
Why?
|
| Mice, Transgenic | 12 | 2018 | 1033 | 0.340 |
Why?
|
| Interferon-gamma | 7 | 2018 | 241 | 0.340 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1173 | 0.310 |
Why?
|
| Cancer Vaccines | 3 | 2018 | 61 | 0.300 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2018 | 79 | 0.300 |
Why?
|
| Bacterial Translocation | 1 | 2007 | 27 | 0.290 |
Why?
|
| Tumor Escape | 2 | 2019 | 37 | 0.280 |
Why?
|
| Flow Cytometry | 8 | 2017 | 489 | 0.280 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 114 | 0.280 |
Why?
|
| Disease Models, Animal | 6 | 2017 | 2550 | 0.270 |
Why?
|
| Head and Neck Neoplasms | 2 | 2023 | 561 | 0.250 |
Why?
|
| Lymphocytes | 3 | 2022 | 228 | 0.250 |
Why?
|
| Leukemia L1210 | 1 | 2004 | 14 | 0.250 |
Why?
|
| Pentetic Acid | 1 | 2004 | 18 | 0.240 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2016 | 157 | 0.240 |
Why?
|
| Dendritic Cells | 2 | 2017 | 201 | 0.240 |
Why?
|
| Macrophage Activation | 1 | 2004 | 75 | 0.230 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 1070 | 0.230 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 561 | 0.230 |
Why?
|
| CTLA-4 Antigen | 4 | 2022 | 45 | 0.230 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2022 | 17 | 0.210 |
Why?
|
| Bile Duct Neoplasms | 1 | 2022 | 39 | 0.210 |
Why?
|
| Mice, Inbred NOD | 3 | 2018 | 138 | 0.200 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 236 | 0.200 |
Why?
|
| Female | 18 | 2022 | 38074 | 0.200 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 186 | 0.200 |
Why?
|
| Granzymes | 3 | 2017 | 19 | 0.200 |
Why?
|
| Apoptosis | 3 | 2017 | 1641 | 0.200 |
Why?
|
| Mice, SCID | 3 | 2018 | 238 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2021 | 6 | 0.200 |
Why?
|
| gp100 Melanoma Antigen | 3 | 2018 | 16 | 0.200 |
Why?
|
| Propionates | 1 | 2021 | 21 | 0.200 |
Why?
|
| Benzoxazines | 1 | 2021 | 20 | 0.200 |
Why?
|
| Antigens, Neoplasm | 3 | 2017 | 132 | 0.190 |
Why?
|
| Immunity | 2 | 2021 | 67 | 0.190 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2018 | 20 | 0.190 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 2 | 2017 | 8 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 212 | 0.180 |
Why?
|
| Circadian Rhythm | 1 | 2021 | 218 | 0.180 |
Why?
|
| Isoquinolines | 1 | 2020 | 37 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 35 | 0.180 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 34 | 0.180 |
Why?
|
| Precision Medicine | 2 | 2019 | 111 | 0.180 |
Why?
|
| Hemoglobins | 1 | 2020 | 120 | 0.170 |
Why?
|
| Membrane Glycoproteins | 4 | 2017 | 370 | 0.170 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 22 | 0.170 |
Why?
|
| beta Catenin | 2 | 2017 | 73 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 951 | 0.170 |
Why?
|
| Interleukins | 2 | 2010 | 79 | 0.170 |
Why?
|
| Immune Evasion | 1 | 2019 | 19 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2020 | 284 | 0.160 |
Why?
|
| Pyrazoles | 1 | 2020 | 190 | 0.160 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.160 |
Why?
|
| PPAR gamma | 1 | 2019 | 95 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2020 | 330 | 0.160 |
Why?
|
| Male | 13 | 2022 | 37321 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 468 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 299 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 170 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 179 | 0.150 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2017 | 4 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 18 | 0.150 |
Why?
|
| Lysophospholipids | 1 | 2019 | 209 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 201 | 0.150 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 41 | 0.150 |
Why?
|
| CD28 Antigens | 3 | 2015 | 12 | 0.150 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2017 | 24 | 0.150 |
Why?
|
| Italy | 3 | 2022 | 36 | 0.150 |
Why?
|
| Mice, Inbred DBA | 3 | 2008 | 120 | 0.150 |
Why?
|
| Sphingosine | 1 | 2019 | 315 | 0.150 |
Why?
|
| Composite Tissue Allografts | 1 | 2017 | 8 | 0.150 |
Why?
|
| Polylysine | 1 | 2017 | 13 | 0.150 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2017 | 7 | 0.150 |
Why?
|
| Sphingosine N-Acyltransferase | 1 | 2017 | 62 | 0.150 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2017 | 7 | 0.150 |
Why?
|
| Poly I-C | 1 | 2017 | 20 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 174 | 0.140 |
Why?
|
| Interleukin-7 | 1 | 2017 | 18 | 0.140 |
Why?
|
| NAD | 1 | 2017 | 73 | 0.140 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2017 | 17 | 0.140 |
Why?
|
| Hindlimb | 1 | 2017 | 38 | 0.140 |
Why?
|
| GPI-Linked Proteins | 3 | 2014 | 27 | 0.140 |
Why?
|
| Intestines | 2 | 2007 | 114 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2017 | 99 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2021 | 7029 | 0.140 |
Why?
|
| Cyclosporine | 1 | 2017 | 121 | 0.140 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2009 | 268 | 0.140 |
Why?
|
| Complement Inactivating Agents | 1 | 2017 | 56 | 0.140 |
Why?
|
| Colitis | 1 | 2017 | 156 | 0.140 |
Why?
|
| Folate Receptors, GPI-Anchored | 3 | 2004 | 6 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 331 | 0.130 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 32 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2015 | 304 | 0.130 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 514 | 0.130 |
Why?
|
| Vaccination | 1 | 2017 | 189 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2015 | 50 | 0.130 |
Why?
|
| Adaptive Immunity | 1 | 2015 | 37 | 0.130 |
Why?
|
| Receptor Cross-Talk | 1 | 2015 | 16 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2012 | 132 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 129 | 0.120 |
Why?
|
| Antibodies, Bispecific | 1 | 2015 | 12 | 0.120 |
Why?
|
| Cell Movement | 1 | 2017 | 630 | 0.120 |
Why?
|
| Folate Receptor 2 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Protein Engineering | 1 | 2015 | 35 | 0.120 |
Why?
|
| Acetylcysteine | 1 | 2018 | 296 | 0.120 |
Why?
|
| 5'-Nucleotidase | 1 | 2014 | 13 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 231 | 0.120 |
Why?
|
| Sphingolipids | 1 | 2017 | 337 | 0.120 |
Why?
|
| Mice, Knockout | 5 | 2019 | 1692 | 0.120 |
Why?
|
| Immunity, Innate | 1 | 2015 | 156 | 0.120 |
Why?
|
| Graft Survival | 1 | 2017 | 465 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 88 | 0.120 |
Why?
|
| Reperfusion Injury | 1 | 2017 | 320 | 0.120 |
Why?
|
| Research Design | 1 | 2018 | 729 | 0.120 |
Why?
|
| Ceramides | 1 | 2017 | 578 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 332 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 507 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2015 | 122 | 0.110 |
Why?
|
| Antigens, CD | 2 | 2014 | 230 | 0.110 |
Why?
|
| Aged | 7 | 2022 | 14862 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 532 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2010 | 66 | 0.100 |
Why?
|
| K562 Cells | 2 | 2010 | 44 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 2 | 2021 | 104 | 0.100 |
Why?
|
| Immunophenotyping | 3 | 2021 | 110 | 0.100 |
Why?
|
| Inflammation | 1 | 2017 | 1030 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2010 | 1 | 0.090 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2010 | 3 | 0.090 |
Why?
|
| Immune Tolerance | 2 | 2014 | 114 | 0.090 |
Why?
|
| T-Box Domain Proteins | 1 | 2010 | 29 | 0.090 |
Why?
|
| Prognosis | 3 | 2021 | 2093 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 195 | 0.090 |
Why?
|
| Fetal Blood | 1 | 2010 | 131 | 0.090 |
Why?
|
| Cells, Cultured | 5 | 2018 | 2673 | 0.090 |
Why?
|
| MART-1 Antigen | 1 | 2009 | 10 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 35 | 0.090 |
Why?
|
| Spleen | 3 | 2017 | 301 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 714 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2009 | 57 | 0.080 |
Why?
|
| L-Selectin | 3 | 2017 | 28 | 0.080 |
Why?
|
| Medicare | 2 | 2022 | 319 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 151 | 0.080 |
Why?
|
| Blood Group Incompatibility | 1 | 2008 | 7 | 0.080 |
Why?
|
| Rats, Inbred Lew | 2 | 2006 | 150 | 0.080 |
Why?
|
| Major Histocompatibility Complex | 1 | 2008 | 34 | 0.080 |
Why?
|
| Disease Management | 2 | 2021 | 248 | 0.080 |
Why?
|
| Middle Aged | 6 | 2021 | 21147 | 0.080 |
Why?
|
| Survival Rate | 2 | 2021 | 1056 | 0.080 |
Why?
|
| Polymyxin B | 1 | 2007 | 5 | 0.080 |
Why?
|
| Eye | 1 | 2008 | 89 | 0.070 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 23 | 0.070 |
Why?
|
| Vitiligo | 1 | 2007 | 12 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 307 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2007 | 160 | 0.070 |
Why?
|
| Radionuclide Imaging | 2 | 2004 | 166 | 0.070 |
Why?
|
| Hyaluronan Receptors | 3 | 2017 | 142 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2021 | 29 | 0.070 |
Why?
|
| Folic Acid Deficiency | 1 | 2006 | 16 | 0.070 |
Why?
|
| Weight-Bearing | 1 | 2006 | 53 | 0.070 |
Why?
|
| Phenotype | 2 | 2021 | 947 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2008 | 291 | 0.070 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 455 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 498 | 0.060 |
Why?
|
| Rats | 3 | 2014 | 5300 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2022 | 7277 | 0.060 |
Why?
|
| KB Cells | 1 | 2004 | 9 | 0.060 |
Why?
|
| Mutation | 2 | 2021 | 1213 | 0.060 |
Why?
|
| Peptides | 2 | 2018 | 455 | 0.060 |
Why?
|
| Radioisotopes | 1 | 2004 | 40 | 0.060 |
Why?
|
| HeLa Cells | 1 | 2004 | 237 | 0.060 |
Why?
|
| Endocytosis | 1 | 2004 | 113 | 0.060 |
Why?
|
| Antirheumatic Agents | 1 | 2004 | 59 | 0.060 |
Why?
|
| United States | 3 | 2022 | 7367 | 0.060 |
Why?
|
| Ligands | 1 | 2004 | 317 | 0.060 |
Why?
|
| Gene Expression | 2 | 2021 | 770 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2022 | 2 | 0.050 |
Why?
|
| Placenta Growth Factor | 1 | 2022 | 12 | 0.050 |
Why?
|
| Interleukin-5 | 1 | 2022 | 14 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2022 | 25 | 0.050 |
Why?
|
| Simvastatin | 1 | 2023 | 34 | 0.050 |
Why?
|
| Chemokine CCL5 | 1 | 2022 | 23 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 69 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 30 | 0.050 |
Why?
|
| Lovastatin | 1 | 2023 | 78 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 82 | 0.050 |
Why?
|
| Chelating Agents | 1 | 2002 | 47 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 10 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 124 | 0.050 |
Why?
|
| Macaca fascicularis | 1 | 2021 | 31 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 51 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2021 | 40 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 87 | 0.050 |
Why?
|
| Protein Binding | 1 | 2004 | 1027 | 0.050 |
Why?
|
| Propensity Score | 1 | 2021 | 117 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2021 | 14 | 0.050 |
Why?
|
| Genes, MHC Class II | 1 | 2021 | 29 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 334 | 0.050 |
Why?
|
| Genetic Vectors | 2 | 2015 | 312 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2021 | 108 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 80 | 0.050 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2011 | 9 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 84 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 1026 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 420 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2021 | 397 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2020 | 127 | 0.040 |
Why?
|
| Dogs | 1 | 2021 | 490 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2021 | 110 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2019 | 54 | 0.040 |
Why?
|
| Linear Models | 1 | 2021 | 521 | 0.040 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2019 | 63 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 800 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 6 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1054 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 215 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2018 | 76 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 39 | 0.040 |
Why?
|
| Glutamine | 1 | 2017 | 45 | 0.040 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 13 | 0.040 |
Why?
|
| Sirtuin 1 | 1 | 2017 | 47 | 0.040 |
Why?
|
| Immunotherapy, Active | 1 | 2017 | 6 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2017 | 234 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 112 | 0.040 |
Why?
|
| Receptor, Anaphylatoxin C5a | 1 | 2017 | 20 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 53 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2017 | 101 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 1266 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2017 | 48 | 0.040 |
Why?
|
| Glycolysis | 1 | 2017 | 79 | 0.040 |
Why?
|
| Adult | 3 | 2022 | 21403 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 931 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 223 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 145 | 0.040 |
Why?
|
| Haptens | 1 | 2016 | 11 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1293 | 0.030 |
Why?
|
| Complement C3 | 1 | 2017 | 101 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 2083 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2016 | 26 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 546 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 70 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 700 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1864 | 0.030 |
Why?
|
| Models, Animal | 1 | 2017 | 252 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1593 | 0.030 |
Why?
|
| Complement Activation | 1 | 2017 | 145 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 209 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2358 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 167 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 786 | 0.030 |
Why?
|
| Cytokine-Induced Killer Cells | 1 | 2015 | 1 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2015 | 35 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 35 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3259 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 337 | 0.030 |
Why?
|
| Apyrase | 1 | 2014 | 10 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 786 | 0.030 |
Why?
|
| Chemokines | 1 | 2015 | 119 | 0.030 |
Why?
|
| Arthritis | 1 | 2014 | 53 | 0.030 |
Why?
|
| Calcium | 1 | 2017 | 929 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 267 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1342 | 0.030 |
Why?
|
| Kinetics | 1 | 2014 | 1047 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 4848 | 0.030 |
Why?
|
| Receptors, CCR7 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 384 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 41 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 129 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2011 | 59 | 0.020 |
Why?
|
| CpG Islands | 1 | 2011 | 51 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 71 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2010 | 17 | 0.020 |
Why?
|
| Electroporation | 1 | 2010 | 11 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 119 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2011 | 193 | 0.020 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2009 | 2 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2009 | 5 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Receptors, NK Cell Lectin-Like | 1 | 2009 | 1 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 132 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 57 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 64 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1040 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 852 | 0.020 |
Why?
|
| Graft vs Tumor Effect | 1 | 2008 | 2 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 4655 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 331 | 0.020 |
Why?
|
| Receptors, Interferon | 1 | 2008 | 8 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 134 | 0.020 |
Why?
|
| Remission Induction | 1 | 2008 | 111 | 0.020 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2008 | 3 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 24 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 15 | 0.020 |
Why?
|
| Interferon Type I | 1 | 2008 | 32 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2008 | 242 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2008 | 147 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 981 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 34 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 320 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2010 | 1664 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 163 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 710 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2006 | 42 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2006 | 97 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 782 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2006 | 94 | 0.020 |
Why?
|
| Autoantigens | 1 | 2006 | 91 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 682 | 0.020 |
Why?
|
| Antibodies | 1 | 2006 | 241 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 245 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 2002 | 109 | 0.010 |
Why?
|
| Technetium | 1 | 2002 | 38 | 0.010 |
Why?
|